Since we observed that AnxA5 administration following cisplatin treatment increased the level of TNF-a and decreased the level of TGF-3 within the TME, we sought to characterize how the alteration of these cytokine levels affects the TME by treating TC-1 tumor-bearing mice receiving cisplatin and/or E7 long peptide administration with anti-TNF-a or anti-TGF-3 blocking antibody (Fig. 3a). This evidence concerns the gene ANXA5 and neoplasm.